Huang, Yan <br/><br/>
The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.  [electronic resource] 

 -  Orphanet journal of rare diseases  03 2017 
 - 49 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1750-1172 
<br/><br/><label>Standard No.: </label>10.1186/s13023-017-0605-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Barth Syndrome--drug therapy<br/>Bezafibrate--therapeutic use<br/>Blotting, Western<br/>Cardiolipins--metabolism<br/>Cardiomyopathies--drug therapy<br/>Disease Models, Animal<br/>Echocardiography<br/>Female<br/>Male<br/>Mice<br/>Peroxisome Proliferator-Activated Receptors--agonists<br/>Polymerase Chain Reaction